ALK Inhibitors or Chemotherapy for Third Line in ALK-positive NSCLC? Real-world Data.

ABSTRACT:

Objectives

ALK inhibitors (ALKi) are the standard-of-care treatment for metastatic ALK-rearranged non-small cell lung cancer (NSCLC) in the first- and second-line setting. We conducted a real-world multi-institutional analysis, aiming to compare the efficacy of third-line ALKi versus chemotherapy in these patients.

Methods

Consecutive ALK-positive metastatic NSCLC patients treated with at least one ALKi were identified in the working databases of 7 Israeli oncology centers (the full cohort). Demographic and clinical data were collected. Patients receiving any systemic treatment beyond 2 ALKi comprised the third-line cohort, whether a third ALKi (group A) or chemotherapy (group B). Groups A and B were compared in terms of overall survival (OS) and time-to-next-treatment line

SUBMITTER: Moskovitz M 

PROVIDER: S-EPMC8842297 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature